Delivery technologies for therapeutic targeting of fibronectin fibrosis in autoimmunity and applications

Fibronectin (FN) is a critical component of extracellular matrix (ECM) contributing to various physiological processes, including tissue repair and immune response regulation. FN regulates various cellular functions such as adhesion, proliferation, migration, differentiation, and cytokine release. Alterations in FN expression, deposition, and molecular structure can profoundly impact its interaction with cells, growth factors, ECM components, and associated signaling pathways, thus influencing the progress of diseases such as fibrosis and autoimmune disorders. Therefore, developing therapeutics that directly target FN, or its interaction with cells and other ECM components can be an intriguing approach to address autoimmune and fibrosis pathogenesis.